CERo Therapeutics Inc. (CERO)
0.58
-0.09 (-13.56%)
At close: Apr 15, 2025, 3:58 PM
0.55
-4.36%
After-hours: Apr 15, 2025, 05:42 PM EDT
-13.56% (1D)
| Bid | 0.55 |
| Market Cap | 1.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.26M |
| EPS (ttm) | -118.56 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.63 |
| Volume | 812,236 |
| Avg. Volume (20D) | 704,322 |
| Open | 0.67 |
| Previous Close | 0.67 |
| Day's Range | 0.55 - 0.67 |
| 52-Week Range | 0.55 - 184.00 |
| Beta | 0.73 |
About CERO
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California....
Industry Biotechnology
Sector Healthcare
IPO Date Nov 30, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol CERO
Website https://www.cero.bio
4 months ago
+7.68%
CERo Therapeutics Holdings shares are trading high...
Unlock content with
Pro Subscription
5 months ago
+52.4%
CERo Therapeutics shares are trading higher after the company received FDA clearance for its investigational new drug application to initiate a Phase 1 clinical trial of CER-1236 for acute myelogenous leukemia.
